These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 38457222

  • 21. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP, Zhong HJ, Huang YH, Gao XD, Zhao X, Shen Y, Cheng S, Huang JY, Chen SJ, Wang L, Zhao WL.
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [Abstract] [Full Text] [Related]

  • 22. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L, Marjanovic G, Macukanovic-Golubovic L, Krstic M, Jevtovic-Stoimenov T, Kostov M, Smelcerovic Z, Stojanovic M.
    J BUON; 2016 Feb; 21(5):1259-1267. PubMed ID: 27837631
    [Abstract] [Full Text] [Related]

  • 23. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U.
    J Clin Oncol; 2021 Apr 20; 39(12):1317-1328. PubMed ID: 33621109
    [Abstract] [Full Text] [Related]

  • 24. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM.
    Oncotarget; 2016 Jul 05; 7(27):41242-41250. PubMed ID: 27183909
    [Abstract] [Full Text] [Related]

  • 25. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
    He HX, Gao Y, Bai B, Wang XX, Li JB, Huang C, Mao JY, Ping LQ, Rong QX, He YX, Huang H, Cai QQ, Li ZM, Jiang WQ, Huang HQ.
    Cancer Med; 2021 Nov 05; 10(21):7650-7664. PubMed ID: 34581023
    [Abstract] [Full Text] [Related]

  • 26. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB.
    Ann Hematol; 2017 Nov 05; 96(11):1867-1871. PubMed ID: 28803429
    [Abstract] [Full Text] [Related]

  • 27. [A Retrospective Study of R±DHAX Regimen versus R-CHOP Regimen First-Line Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma].
    Wei WP, Yu XQ, Wang LX, Zhang S, Fei XM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun 05; 32(3):718-722. PubMed ID: 38926958
    [Abstract] [Full Text] [Related]

  • 28. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U.
    J Hematol Oncol; 2020 Jun 06; 13(1):71. PubMed ID: 32505213
    [Abstract] [Full Text] [Related]

  • 29. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
    Zhang MC, Fang Y, Wang L, Cheng S, Fu D, He Y, Zhao Y, Wang CF, Jiang XF, Song Q, Xu PP, Zhao WL.
    Clin Epigenetics; 2020 Oct 23; 12(1):160. PubMed ID: 33097085
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S, Painschab MS, Kaimila B, Kasonkanji E, Zuze T, Tomoka T, Mulenga M, Nyasosela R, Chikasema M, Mtangwanika A, Chawinga M, Mhango W, Nicholas S, Chimzimu F, Kampani C, Krysiak R, Lilly A, Randall C, Seguin R, Westmoreland KD, Montgomery ND, Fedoriw Y, Gopal S.
    Lancet Glob Health; 2021 Jul 23; 9(7):e1008-e1016. PubMed ID: 34022150
    [Abstract] [Full Text] [Related]

  • 31. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P, Jiang SY, He XH, Qin Y, Gui L, Zhou SY, Yang JL, Yang S, Wen TY, Shi YK.
    Zhonghua Zhong Liu Za Zhi; 2020 Mar 23; 42(3):234-241. PubMed ID: 32252203
    [Abstract] [Full Text] [Related]

  • 32. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 33. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
    Cooper A, Tumuluru S, Kissick K, Venkataraman G, Song JY, Lytle A, Duns G, Yu J, Kotlov N, Bagaev A, Hodkinson B, Srinivasan S, Smith SM, Scott DW, Steidl C, Godfrey JK, Kline J.
    J Clin Oncol; 2024 Feb 01; 42(4):467-480. PubMed ID: 38079587
    [Abstract] [Full Text] [Related]

  • 34. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
    Masir N, Akhter A, Roshan TM, Florence CS, Abdul-Rahman F, Tumian NR, Kean-Chang P, Elyamany G, Shabani-Rad MT, Mansoor A.
    J Clin Pathol; 2019 Sep 01; 72(9):630-635. PubMed ID: 31189540
    [Abstract] [Full Text] [Related]

  • 35. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
    Chang JE, Seo S, Kim KM, Werndli JE, Bottner WA, Rodrigues GA, Sanchez FA, Saphner TJ, Longo WL, Kahl BS.
    Clin Lymphoma Myeloma Leuk; 2010 Oct 01; 10(5):379-84. PubMed ID: 21030351
    [Abstract] [Full Text] [Related]

  • 36. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 37. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX, Zou SH, Li F, Li JM, Wang JM, Chen FY, Cao JN, Wang C, Wei Z, Cheng YF.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr 01; 33(4):257-60. PubMed ID: 22781712
    [Abstract] [Full Text] [Related]

  • 38. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
    Villacampa G, Dienstmann R, Bosch F, Abrisqueta P.
    Ann Hematol; 2021 Dec 01; 100(12):2969-2978. PubMed ID: 34378095
    [Abstract] [Full Text] [Related]

  • 39. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T, Seo S, Fuse H, Ishii G, Itoh K, Yano T, Kaneko K, Tsukasaki K.
    Cancer Med; 2019 Mar 01; 8(3):982-989. PubMed ID: 30730104
    [Abstract] [Full Text] [Related]

  • 40. Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
    Wang X, Yu L, Jiang X, Ding K.
    Cancer Med; 2023 May 01; 12(9):10553-10562. PubMed ID: 36912128
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.